Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Interactions between the histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) and the cyclin-dependent kinase (CDK) inhibitor flavopiridol (FP) were examined in human leukemia cells. Simultaneous exposure (24 h) of myelomonocytic leukemia cells (U937) to SAHA (1 microM) and FP (100 nM), which were minimally toxic alone (1.5 +/- 0.5% and 16.3 +/- 0.5% apoptosis respectively), produced a dramatic increase in cell death (ie 63.2 +/- 1.9% apoptotic), reflected by morphology, procaspase-3 and -8 cleavage, Bid activation, diminished DeltaPsi(m), and enhanced cytochrome c release. FP blocked SAHA-mediated up-regulation of p21(CIP1) and CD11b expression, while inducing caspase-dependent Bcl-2 and pRb cleavage. Similar interactions were observed in HL-60 and Jurkat leukemic cells. Enhanced apoptosis in SAHA/FP-treated cells was accompanied by a marked reduction in clonogenic surivival. Ectopic expression of either dominant-negative caspase-8 (C8-DN) or CrmA partially attenuated SAHA/FP-mediated apoptosis (eg 45 +/- 1.5% and 38.2 +/- 2.0% apoptotic vs 78 +/- 1.5% in controls) and Bid cleavage. SAHA/FP induced-apoptosis was unaffected by the free radical scavenger L-N-acetyl cysteine or the PKC inhibitor GFX. Finally, ectopic Bcl-2 expression marginally attenuated SAHA/FP-related apoptosis/cytochrome c release, and failed to restore clonogenicity in cells exposed to these agents. Together, these findings indicate that SAHA and FP interact synergistically to induce mitochondrial damage and apoptosis in human leukemia cells, and suggest that this process may also involve engagement of the caspase-8-dependent apoptotic cascade.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors are active against class I and class II HDACs, and have the ability to induce multiple effects within cells, including cell differentiation, induction of cell cycle arrest, and suppression of tumor growth (Jung et al., 1999; Almenara et al., 2002; Richon et al., 1998; Yoshida et al., 1990a, 1990b).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Almenara et al., 2002
Citations
Cites
An APAF-1·Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9
Zou, H., Li, Y., Liu, X., & Wang, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11549 · Cited by 2,090
Cheng, E. H.-Y. A., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., & Korsmeyer, S. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00320-3 · Cited by 1,707
Conversion of Bcl-2 to a Bax-like Death Effector by Caspases
Cheng, E. H.-Y., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., Ueno, K., & Hardwick, J. M. (1997) · Science · doi:10.1126/science.278.5345.1966 · Cited by 1,107
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation
McKinsey, T. A., Zhang, C.-L., Lu, J., & Olson, E. N. (2000) · Nature · doi:10.1038/35040593 · Cited by 1,052
Gross, A., Yin, X.-M., Wang, K., Wei, M. C., Jockel, J., Milliman, C., Erdjument-Bromage, H., Tempst, P., & Korsmeyer, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.1156 · Cited by 1,045
Sodium butyrate inhibits histone deacetylation in cultured cells
Candido, E. (1978) · Cell · doi:10.1016/0092-8674(78)90305-7 · Cited by 1,036
Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis
Sun, X.-M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., & Cohen, G. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.5053 · Cited by 820
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 678
Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation
Asada, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1223 · Cited by 586
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
p21 WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells
Archer, S. Y., Meng, S., Shei, A., & Hodin, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6791 · Cited by 535
Mitochondrion as a Novel Target of Anticancer Chemotherapy
Costantini, P. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.13.1042 · Cited by 532
Resistance to Apoptosis Conferred by Cdk Inhibitors During Myocyte Differentiation
Wang, J., & Walsh, K. (1996) · Science · doi:10.1126/science.273.5273.359 · Cited by 489
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 488
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420
Medina, V., Edmonds, B., Young, G. P., James, R., Appleton, S., & Zalewski, P. D. (1997) · PubMed · Cited by 377
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
Senderowicz, A. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006353008903 · Cited by 330
Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 284
Self-citationBible, K. C., & Kaufmann, S. H. (1997) · PubMed · Cited by 271
Mechanisms of action of flavopiridol
Sedlacek, H. H. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00124-4 · Cited by 239
Bible, K. C., & Kaufmann, S. H. (1996) · PubMed · Cited by 203
Yin, D. X., & SCHIMKE, R. T. (1995) · PubMed · Cited by 155
Inhibitors of histone deacetylase are potentially effective anticancer agents.
Marks, P. A., Rifkind, R. A., Richon, V. M., & Breslow, R. (2001) · PubMed · Cited by 140
Lee, B. I., Park, S. H., Kim, J. W., Sausville, E. A., Kim, H. T., Nakanishi, O., Trepel, J. B., & Kim, S. J. (2001) · PubMed · Cited by 131
Flavopiridol binds to duplex DNA.
Bible, K. C., Bible, R. H., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y., Hajdu, E., & Kaufmann, S. H. (2000) · PubMed · Cited by 113
Senderowicz, A. M. (2001) · Leukemia · doi:10.1038/sj.leu.2401994 · Cited by 100
Dangond, F., & Gullans, S. R. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8891 · Cited by 96
Rosato, R., Wang, Z., Gopalkrishnan, R., Fisher, P., & Grant, S. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.1.181 · Cited by 87
Self-citationDecker, R. H., Dai, Y., & Grant, S. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400868 · Cited by 81
Self-citationWang, S., Vrana, J. A., Bartimole, T. M., Freemerman, A. J., Jarvis, W. D., Kramer, L. B., Krystal, G. W., Dent, P., & Grant, S. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.6.1000 · Cited by 80
Self-citationGore, S. D., Samid, D., & Weng, L. J. (1997) · PubMed · Cited by 74
Bcl-2 Independence of Flavopiridol-induced Apoptosis
Achenbach, T. V., Müller, R., & Slater, E. P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005267200 · Cited by 69
Wang, S., Wang, Z., Boise, L., Dent, P., & Grant, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0669 · Cited by 66
Self-citationRosato, R. R., Almenara, J. A., Cartee, L., Betts, V., Chellappan, S., & Grant, S. (2002) · PubMed · Cited by 66
Self-citationFreemerman, A. J., Vrana, J. A., Tombes, R. M., Jiang, H., Chellappan, S., Pb, F., & Grant, S. (1997) · Leukemia · doi:10.1038/sj.leu.2400625 · Cited by 65
Self-citationFattman, C. L., Delach, S. M., Dou, Q. P., & Johnson, D. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204414 · Cited by 63
p21Cip1/WAF1 is important for differentiation and survival of U937 cells
Asada, M., Yamada, T., Fukumuro, K., & Mizutani, S. (1998) · Leukemia · doi:10.1038/sj.leu.2401228 · Cited by 57
Wang, Z., Su, Z.-Z., Fisher, P. B., Wang, S., VanTuyle, G., & Grant, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4191 · Cited by 56
Self-citationCartee, L., Wang, Z., Decker, R. H., Chellappan, S., Fusaro, G., Hirsch, K. G., Sankala, H. M., Dent, P., & Grant, S. (2001) · PubMed · Cited by 52
Self-citationWang, Z., Tuyle, G. V., Conrad, D. H., Fisher, P. B., Dent, P., & Grant, S. (1999) · PubMed · Cited by 51
Self-citationMeinhardt, G., Roth, J., & Hass, R. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400709 · Cited by 45
Selvakumaran, M., Reed, J., Liebermann, D. A., & Hoffman‐Liebermann, B. (1994) · Blood · doi:10.1182/blood.v84.4.1036.1036 · Cited by 40
Tang, L., Boise, L., Dent, P., & Grant, S. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00463-9 · Cited by 38
Self-citationVrana, J. A., & Grant, S. (2001) · Blood · doi:10.1182/blood.v97.7.2105 · Cited by 34
Self-citationStinson, S. F., Hill, K. D., Siford, T. J., Phillips, L. R., & Daw, T. W. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050815 · Cited by 21
Hoffman, D. R., & Huberman, E. (1982) · Carcinogenesis · doi:10.1093/carcin/3.8.875 · Cited by 20
Research works printed but not linked: 1
- Rosato RR, Almenara JA, Cartee L, Betts V, Chellappan SP, Grant S . The cyclin-dependent kinase inhibitor flavopiridol disrupts butyrate-induced p21CIP1 expression and maturation while enhancing apoptosis in human myeloid leukemia cells MolCancer Ther 2002 1: 253–266
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“Blocking NF-kB activation by I Kappa B Alpha (IkBa) phosphorylation inhibitor Bay 11-7082 markedly increase HDACi-induced apoptosis (Almenara et al., 2002; Rosato and Grant, 2005).”
BackgroundCyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Metadata
- Authors
- Almenara, J., Rosato, R., & Grant, S.
- Affiliations
- Virginia Commonwealth University (US)
- Venue
- Leukemia
- Published
- 2002-07-01
- Volume
- 16
- Issue
- 7
- Pages
- 1331-1343
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2331221462
- Cited by
- 141
- References
- 50
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 3 · 2014: 7 · 2013: 10 · 2012: 4
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health (5r01ca083705-04)
- National Cancer Institute (CA 83705, CA63753, R01CA063753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- flavopiridol, vorinostat, histone deacetylase inhibitors, cyclin-dependent kinase inhibitors, drug synergy, apoptosis, mitochondrial damage, cytochrome c release, caspase-8, Bid, Bcl-2, p21, leukemia cells, U937 cells, HL-60 cells, Jurkat, clonogenic survival, CrmA
- MeSH terms
- Vorinostat, Antineoplastic Agents, Drug Synergism, Enzyme Inhibitors, Flavonoids, Humans, Hydroxamic Acids, Leukemia, Mitochondria, Piperidines, Apoptosis, Cyclin-Dependent Kinases, HL-60 Cells, Caspases, U937 Cells, Caspase 8, Caspase 9, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.